Paik, James M.
Inova Health System · Inova Fairfax Hospital
6 papers on CoChatORCID 0000-0003-2294-323X
Most cited papers
- Verified
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 3,383
- Verified
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 2,235
- Verified
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 416
- Verified
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 321
- Verified
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 113
- Verified
Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)
Henry, A., Paik, J. M., Austin, P., Eberly, K. E., Golabi, P., Younossi, I., Henry, L., Gerber, L., & Younossi, Z. M. (2023) · Alimentary Pharmacology & Therapeutics
Liver Disease Diagnosis and TreatmentPhysical Activity and Health
Cited by 61
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free